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CASE-LETTER
Bacteremia Due to
Vancomycin-Resistant Leuconostoc
lactis in a Patient With Pneumonia
and Abdominal Infection
L euconostoc lactis is a gram-positive facultative anaerobiccoccus or coccobacillus, catalase and oxidase negative, which
grow in pairs and chains, forming colonies morphologically mis-
taken for Enterococcus or Streptococcus viridans by routine bio-
chemical testing in the clinical microbiology laboratories. This
organism is leucine aminopeptidase–positive and produces gas
from glucose. L lactis is intrinsically resistant to vancomycin
because its pentapeptide cell wall precursors end in a depsipeptide
(alanine-lactate) rather than in the alanine-alanine dipeptide,
which is the binding site for vancomycin in susceptible gram-
positive cocci.1 L lactis is usually cross-resistant to teicoplanin. It
is found in vegetables, legumes, fruits, and meat and is used by
the food industry in the elaboration of dairy products, wine, and
sugars; more rarely, it can be found in human stool and vaginal
specimens.2
In the past, L lactis was not thought to be pathogenic to
humans, but occasional cases of infections caused by this organ-
ism such as ventriculitis,3 osteomyelitis,4 and bloodstream infec-
tion2,5,6 have been reported in recent years. We have found only 3
cases of bacteremia caused by L lactis. We describe what we
believe is the ﬁrst reported case of bloodstream infection due to
L lactis ﬁnally identiﬁed by both matrix-assisted laser desorption/
ionization time-of-ﬂight mass spectrometry (MALDI-TOF-MS)
and 16S rRNA gene partial sequencing.
An 83-year-old Asian woman with cholecystolithiasis
presented with a month history of abdominal pain, diarrhea, and
nausea. Three days after cholecystotomy, this patient was
admitted to intensive care unit (ICU) because of pneumonia
and abdominal infection with temperature of 39.8°C. A central
venous catheter was placed, and parenteral nutrition was admin-
istered for supportive treatment. In the ﬁrst week, she was
treated with intravenous meropenem for pneumonia due to
extended-spectrum beta-lactamase-producing Klebsiella pneu-
moniae and with intravenous vancomycin for 17 days because
of abdominal infection caused by Enterococcus faecium.
Next, she was treated with intravenous cefoperazone/sulbac-
tam and oral minocycline for 2 weeks due to multidrug-
resistant Acinetobacter baumannii complex isolated from
ascitic ﬂuid and sputum. By the 27th day after admission to
the ICU, linezolid was added to the antibiotic regimen because
of L lactis isolated from blood samples. On day 32, the patient
died because of acute obstructive cholangitis and shock.
The patient was continuously febrile throughout the
admission with elevated white blood cell count (high of 16.0 3
109 per liter, 91.0% neutrophils) consistent with a serious infec-
tion and/or sepsis. Ascitic ﬂuid analysis also showed 3,612 white
blood cells per milliliter (88.0% neutrophils). Her chest com-
puted tomography scan, performed on ICU day 7, revealed
bilateral multifocal nodular and patchy consolidation in both
lungs and a small right pleural effusion. On ICU day 27, blood
cultures were drawn into BACTEC Plus Aerobic/F and Lytic/10
Anaerobic/F Medium (Becton Dickinson, Franklin Lakes, NJ)
and incubated in the BACTEC 9240 automated blood culture
system (Becton Dickinson, Cockeysville, MD) according to the
manufacturer’s instructions. After 24 hours of incubation, the
Aerobic/F Medium blood culture was ﬂagged as positive, and
gram-positive cocci in chains were seen. However, Anaerobic/F
Medium was continuously negative after 120 hours. The ﬂuid
was inoculated on bacteriological agars (Oxoid, Basingstoke,
United Kingdom) for 24 hours at 37°C. The bacteria formed
small, circular, smooth, convex, gray, and alpha-hemolytic col-
onies on sheep blood agar and did not grow on MacConkey agar
or Mueller-Hinton agar. The organisms were catalase-negative,
oxidase-negative, gram-positive, ovoid cocci, often seen in pairs
or chains. Identiﬁcation was performed by VITEK 2-compact
system (BioMérieux, Marcy l’Etoile, France) using VITEK
2 GP identiﬁcation card (BioMérieux, Hazelwood, MO), as
instructed by the manufacturer. The isolate gave positive reac-
tions for a-galactosidase, D-galactose, N-acetyl-D-glucosamine,
D-maltose, D-mannose, D-rafﬁnose, and saccharose and grew in
6.5% NaCl. It was resistant to polymyxin B, optochin, and
novobiocin and was identiﬁed as Leuconostoc pseudomesenter-
oides with a probability of 94% after incubation for 8 hours. The
catheter tip culture was negative and the follow-up blood cul-
tures were also negative. Subsequently, the isolate was identiﬁed
as L lactis by 2 MALDI-TOF MS systems, BioMérieux VITEK-
MS mass spectrometer (99.9% probability) and Bruker Autoﬂex
Speed mass spectrometer (log score 2.089). The identity was
conﬁrmed as L lactis by 16S rRNA gene partial sequencing.
Universal bacterial primers 27F and 1494R were used for ampli-
ﬁcation.2 Puriﬁed DNA from the PCR was sequenced with Big-
Dye Terminator Cycle sequencing kit (Applied Biosystems,
Foster City, CA) and Applied Biosystems ABI PRISM 3730
genetic analyzer (Applied Biosystems Division). All sequences
were compared with those of similar strains using BLAST and
EzTaxon.2 The isolates showed 98% sequence similarity to L
lactis (GenBank Accession No. AB904777).
There are no CLSI or EUCAST susceptibility criteria for
this unusual organism, so it is hard to evaluate susceptibility
determinations. Minimal inhibitory concentration was deter-
mined by VITEK 2-compact system using VITEK 2 AST-GP68
card (BioMérieux, Hazelwood, MO). Minimal inhibitory con-
centrations were as follows: vancomycin, $2 mg/mL; erythro-
mycin, $1 mg/mL; ertapenem, $8 mg/mL; meropenem,
$4 mg/mL; amoxicillin, 1 mg/mL; levoﬂoxacin, 2 mg/mL;
moxiﬂoxacin, 0.5 mg/mL; tetracycline, 4 mg/mL; chloromyce-
tin, #2 mg/mL; trimethoprim and sulphamethoxazole,
#10 mg/mL; telithromycin, #0.25 mg/mL. Because the patient
was on vancomycin, susceptibility to this antibiotic seemed
unlikely. Antimicrobial sensitivities were repeated by disk dif-
fusion method on sheep blood agar (Oxoid) and revealed that the
isolate was resistant to vancomycin. Zone diameter showed the
following: vancomycin, 6 mm; teicoplanin, 6 mm; trimethoprim
and sulphamethoxazole, 6 mm; meropenem, 14 mm; imipe-
nem, 16 mm; rifampicin, 11 mm; ciproﬂoxacin, 16 mm; levo-
ﬂoxacin, 19 mm; erythromycin, 21 mm; linezolid, 23 mm;
chloromycetin, 19 mm; cefepime, 19 mm; ceftriaxone,
18 mm; cefotaxime, 21 mm; ampicilin, 24 mm; amikacin,
20 mm; gentamycin, 22 mm; clindamycin, 25 mm; tetracycline,
18 mm; minocycline, 19 mm; ceftazidime, 24 mm; penicillin,
27 mm; piperacillin, 30 mm; cefoperazone/sulbactam, 31 mm;
ticarcillin/clavulanic acid, 31 mm; ampicilin/sulbactam,
26 mm; piperacillin/tazobatam, 31 mm.
In the past, Leuconostoc spp. were listed as members of
the Streptococcaceae but are now recognized as Leuconostoca-
ceae and are placed within the order Lactobacillales. The iden-
tiﬁcation of L lactis as a cause of infection can be difﬁcult as it
is catalase-negative and gram-positive cocci, and colony
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morphology resembles a Streptococcus. Suspicion of an alter-
native pathogen is raised only when sensitivities reveal vanco-
mycin resistance. If sensitivities are omitted, the organism may
remain misclassiﬁed and potentially dismissed as a blood cul-
ture contaminant because of its resemblance to Streptococcus
viridans, or mistreated as an Enterococcus. The failure of auto-
mated bacterial identiﬁcation systems to identify the organism
may contribute to an underestimate of its pathogenicity. It has
been demonstrated that the VITEK 2 system failed to accurately
identify Leuconostoc at the species level and that the accuracy
rate was only 15% compared with that of 16S rRNA gene
partial sequencing.7 We conﬁrm that molecular methods more
accurately identify such organisms and demonstrate that
MALDI-TOF MS also provides accurate identiﬁcation.
Risk factors for infection by L lactis include central
venous catheters, parenteral nutrition, surgery, liver failure,
chronic renal insufﬁciency treated with hemodialysis, extensive
burns, compromised immunity, and previous antibiotic therapy,
particularly with vancomycin.2 The skin and digestive tract are
believed to play important roles as routes of entry into the body.
Vancomycin therapy and long-term intravenous nutrition,
through a central venous catheter, might have played some role
in the development of L lactis bacteremia in this patient. Long-
term vancomycin administration may have contributed to over-
growth of usual gastrointestinal microbial ﬂora by L lactis by
selectively suppressing the growth of other vancomycin-
susceptible gram-positive organisms.
Proper management of the patient with L lactis bacteremia
includes the removal of the infected foci of infection such as the
central catheter or by the drainage of abscesses, and administra-
tion of appropriate antibiotics. There are no standards for select-
ing antimicrobial agents to treat Leuconostoc spp. The treatment
of choice seems to be penicillin or ampicillin, but clindamycin,
linezolid, macrolides, aminoglycosides, cephalosporins, and tet-
racyclines have also been used.2,4,5 Susceptibility to trimethoprim
and sulphamethoxazole is variable, with some reported cases of
infection in patients who were already receiving this drug. We
chose to use linezolid for our patient, but we could not evaluate
its effect as the patient died because of acute obstructive cholan-
gitis and shock 4 days later. We also could not be certain whether
L lactis bacteremia itself was the cause of death for our patient.
Because of the rarity of case reports of L lactis, the fatality rate of
this pathogen is not known.
With the increasing use of vancomycin in clinical practice,
some new vancomycin-resistant pathogenic bacteria are likely to
appear. We emphasize the importance of performing tests of
sensitivity to vancomycin to properly identify L lactis. This may
allow the reporting of new cases and help to discover the prev-
alence and frequency of the infection caused by this pathogen. It
is almost certainly more common than generally recognized, and
the use of an opportunistic pathogen in food fermentation may be
questionable.
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